Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Sensitizing EGFR Gene Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 3 of 0 results

Testing effectiveness (Phase 2)UnknownNCT05326425
What this trial is testing

Lazertinib in Patients With NSCLC With Asymptomatic or Mild Symptomatic Brain Metastases After Failure of EGFR TKI.

Who this might be right for
Lung Neoplasms
Jin Hyoung Kang 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07551414
What this trial is testing

Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI

Who this might be right for
NSCLC (Non-small Cell Lung Carcinoma)Leptomeningeal MetastasisEGFR-TKI Sensitizing Mutation+1 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 38
Not applicableUnknownNCT04930133
What this trial is testing

Retrospective Multi-cohort Study of Frontline Afatinib Followed by 2nd Line Therapy Including Osimertinib, Chemotherapy or Other Therapy

Who this might be right for
NSCLC
Seoul St. Mary's Hospital 737